Melon Globalcare Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Melon Globalcare Pharmaceutical Export Portfolio Dataset — 3 Products, $43.7K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Melon Globalcare — Pharmaceutical Exporter Profile (2026) | 3 Products, $43.7K Trade | TransData Nexus

Melon Globalcare

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $43.7K Total Trade · DGFT Verified

Melon Globalcare is an Indian pharmaceutical exporter with a total trade value of $43.7K across 3 products in 2 therapeutic categories. Based on 27 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Daratumumab ($27.4K), Carfilzomib ($8.3K), Ledipasvir ($8.1K).

Melon Globalcare — Export Portfolio & Destination Treemap

Melon Globalcare pharmaceutical export portfolio — 3 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Melon Globalcare? — Company Overview & Market Position

Melon Globalcare, established in 2018, is a Mumbai-based pharmaceutical exporter specializing in the global distribution of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company operates as a partnership, with Mr. Ronit Kothari serving as the Managing Partner. While specific details regarding the company's Corporate Identification Number (CIN) and revenue are not publicly disclosed, Melon Globalcare employs a team of approximately 10 individuals. The company's official website is www.melonglobalcare.com.

The company has established a strong presence in the pharmaceutical industry, exporting a diverse range of products to various international markets. Their product portfolio includes anti-cancer medications, HIV treatments, and other therapeutic drugs, reflecting a commitment to addressing critical health needs globally.

What Does Melon Globalcare Export? — Product Portfolio Analysis

Top Products by Export Value

1Daratumumab$27.4K 2Carfilzomib

Product Portfolio — Top 3 by Export Value

Melon Globalcare exports 3 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Daratumumab	Advanced Oncology	$27.4K	11	2.0%	13
2	Carfilzomib	Advanced Oncology	$8.3K	5	0.7%	8
3	Ledipasvir	Antiviral & HIV Medications	$8.1K	11	0.7%	13

Melon Globalcare exports 3 pharmaceutical products across 2 therapeutic categories with a total export value of $43.7K. The top category is Advanced Oncology (81.5% of portfolio), followed by Antiviral & HIV Medications (18.5%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Melon Globalcare — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Melon Globalcare operates from its headquarters located at Mazgaon Koliwada Road, Mumbai, Maharashtra, India. While the company serves as a third-party manufacturer, trader, and bulk exporter, specific details regarding the locations, capacities, and specializations of its manufacturing facilities are not publicly disclosed. The company emphasizes quality assurance and timely delivery, ensuring that all pharmaceutical products meet stringent standards before reaching international markets.

3Key Leadership

Mr. Ronit Kothari serves as the Managing Partner of Melon Globalcare. Under his leadership, the company has expanded its global footprint, exporting pharmaceutical products to countries such as the United States, Germany, Saudi Arabia, and Sri Lanka. The company's team comprises skilled professionals dedicated to maintaining high-quality standards and ensuring timely delivery of products to international clients.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Melon Globalcare Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Melon Globalcare has established a presence in several regulated markets, including the United States, Germany, Saudi Arabia, and Sri Lanka. The company exports a range of pharmaceutical products, including anti-cancer medications and HIV treatments, to these countries. While specific details regarding regulatory filings, approvals, and market access status in these regions are not publicly disclosed, the company's adherence to international quality standards and its partnerships with reputable manufacturers suggest compliance with regulatory requirements.

In the United States, Melon Globalcare's products are likely subject to the Food and Drug Administration (FDA) regulations. The company's commitment to quality assurance and ethical business practices indicates a focus on meeting FDA standards for pharmaceutical exports. Similarly, in the European Union, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees pharmaceutical products, and Melon Globalcare's adherence to international quality norms suggests compliance with EU regulations. In Australia, the Therapeutic Goods Administration (TGA) regulates pharmaceutical products, and the company's global distribution network indicates potential compliance with TGA standards. In Japan, the Pharmaceuticals and Medical Devices Agency (PMDA) oversees pharmaceutical products, and Melon Globalcare's international presence suggests adherence to PMDA regulations.

2Emerging Markets

Melon Globalcare — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Melon Globalcare's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed. However, the company's export activities to the United States suggest a focus on compliance with FDA regulations. The company's commitment to quality assurance and ethical business practices indicates an emphasis on meeting FDA standards for pharmaceutical exports.

2WHO & EU GMP

While specific details regarding Melon Globalcare's World Health Organization (WHO) prequalification and European Union Good Manufacturing Practice (EU GMP) certifications are not publicly disclosed, the company's adherence to international quality standards and its partnerships with reputable manufacturers suggest compliance with these certifications. The company's global distribution network and export activities to various countries indicate a commitment to meeting WHO and EU GMP standards.

3CDSCO & Indian Regulatory

Melon Globalcare — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Melon Globalcare operates in a competitive landscape with several key players in the pharmaceutical export sector. Top competitors in overlapping categories include Cipla Ltd, Intas Pharmaceuticals Ltd, and Aurobindo Pharma. These companies have established global distribution networks and a diverse product portfolio. In comparison, Melon Globalcare's focus on exporting anti-cancer and HIV medications positions it in a niche segment, potentially allowing for specialized expertise and targeted market strategies. While specific market share comparisons are not publicly available, Melon Globalcare's strategic focus on quality and timely delivery contributes to its competitive positioning.

2Key Differentiators

Melon Globalcare's key differentiators include its specialized focus on exporting anti-cancer and HIV medications, addressing critical health needs in various regions. The company's commitment to quality assurance and ethical business practices ensures that all pharmaceutical products meet stringent standards before reaching international markets. Additionally, Melon Globalcare's global distribution network and partnerships with reputable manufacturers enable it to offer a reliable marketplace for pharmaceutical supplies worldwide.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Melon Globalcare as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Melon Globalcare has a track record of exporting pharmaceutical products to various international markets, including the United States, Germany, Saudi Arabia, and Sri Lanka. The company's export volume and consistency indicate a reliable supply chain. While specific reliability indicators are not publicly disclosed, the company's adherence to international quality standards and ethical business practices suggests a strong commitment to maintaining product integrity and customer satisfaction.

2Certifications to Verify

Importers should verify the following certifications when considering Melon Globalcare as a supplier:

FDA Approval: Confirm that the company's products are approved by the U.S. Food and Drug Administration (FDA). Verification can be done through the FDA's official website or by contacting the company directly.

WHO-GMP Certification: Ensure that the company holds World Health Organization Good Manufacturing Practice (WHO-GMP) certification. This can be verified by checking the WHO's official website or by requesting certification details from the company.

Frequently Asked Questions — Melon Globalcare

How many pharmaceutical products does Melon Globalcare export from India?

Melon Globalcare exports 3 pharmaceutical products across 2 therapeutic categories. The top exports are Daratumumab ($27.4K), Carfilzomib ($8.3K), Ledipasvir ($8.1K). Total export value is $43.7K.

What is Melon Globalcare's total pharmaceutical export value?

Melon Globalcare's total pharmaceutical export value is $43.7K, based on 27 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Melon Globalcare cover?

Melon Globalcare exports across 2 therapeutic categories. The largest are Advanced Oncology (81.5%, 2 products), Antiviral & HIV Medications (18.5%, 1 products).

Get Full Melon Globalcare Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.